Cocoa Flavanols, (–)-Epicatechin, and Inflammation: What the New Research Really Suggests

Date: March 14, 2026
Contributing Authors: Team TRILITY / ACEND

Focus keyphrase: cocoa flavanols and inflammation

A new wave of research is giving cocoa something it rarely gets in the wellness world: precision. Not “chocolate is healthy” as a vague headline, but a more disciplined question: can standardized cocoa flavanols—especially (–)-epicatechin—meaningfully influence chronic inflammation and the biology of aging?

That question matters because low-grade inflammation is one of the clearest threads linking cardiovascular disease, metabolic dysfunction, vascular decline, and what researchers now call inflammaging—the slow-burning inflammatory burden that tends to rise with age. In a 2025 ancillary analysis from the large COSMOS randomized clinical trial, daily cocoa extract supplementation significantly lowered high-sensitivity C-reactive protein (hsCRP), a widely used marker of systemic inflammation and cardiovascular risk. Participants in the cocoa group took 500 mg of cocoa flavanols daily, including 80 mg of (–)-epicatechin, and hsCRP fell by 8.4% per year relative to placebo. That is a meaningful finding, especially because the intervention was long-term and randomized. 

The nuance is important. The same study did not show equally strong, statistically significant effects across every inflammatory marker tested. IL-6, TNF-α, and IL-10 did not significantly change after multiple-comparison adjustment, although investigators noted signals worth further study, including a modest IL-6 reduction in women. In other words, the most defensible interpretation is not “cocoa stops aging,” but rather that standardized cocoa flavanols may help modulate one important inflammatory pathway associated with aging and cardiovascular risk. 

That distinction became even more relevant after a separate 2026 COSMOS ancillary paper in Nature Medicine looked at DNA methylation–based biological aging clocks. In that study, cocoa extract did not significantly affect the five epigenetic aging measures tested, whereas the multivitamin arm showed small effects on some clocks. So, from an evidence standpoint, cocoa flavanols currently look stronger for inflammatory and vascular support than for direct claims about slowing biological age itself. 

Why hsCRP matters

hsCRP is not a disease by itself, but it is a clinically useful signal. When hsCRP runs high, it often reflects a body experiencing persistent inflammatory stress. Elevated hsCRP has long been associated with higher cardiovascular risk, and in older adults it is part of the broader inflammaging picture that can overlap with arterial stiffness, endothelial dysfunction, and declining metabolic resilience. That is why the 2025 cocoa study drew attention: it connected a nutrition intervention with a measurable reduction in a recognized inflammatory biomarker. 

For ACEND, this is the bigger takeaway. Chronic inflammation is rarely one pathway, one trigger, or one molecule. It is usually a network problem involving immune tone, oxidative stress, vascular signaling, mitochondrial strain, and often gut-derived inflammatory pressure. Cocoa flavanols do not solve that network alone, but the data reinforce an ACEND principle: targeted plant bioactives can measurably influence clinically relevant inflammatory terrain. 

What is (–)-epicatechin, exactly?

(–)-Epicatechin is one of cocoa’s best-studied flavan-3-ols. It is not the only bioactive in cocoa, but it is increasingly viewed as one of the most important contributors to cocoa’s vascular and cardiometabolic effects. In the COSMOS cocoa arm, participants consumed 80 mg of (–)-epicatechin as part of the 500 mg total cocoa flavanol dose. Earlier human work and later reviews have linked epicatechin-rich cocoa intake to improved nitric oxide signaling, better endothelial responsiveness, and favorable changes in cardiometabolic biomarkers. 

Mechanistically, this makes sense. Endothelial tissue—the thin layer lining blood vessels—responds to oxidative stress, inflammatory mediators, and nutrient signals. Cocoa flavanols appear to support nitric oxide bioavailability and vascular reactivity, which may be one reason they continue to show up in cardiovascular nutrition research. A 2019 dose-response meta-analysis found that cocoa flavanols significantly improved endothelial function, with the strongest modeled effect around 710 mg total flavanols and 95 mg (–)-epicatechin. That does not establish a universal ideal dose for everyone, but it does suggest the bioactive target matters more than simply eating “more chocolate.” 

Why “eat chocolate” is the wrong headline

One of the biggest problems with public reporting on cocoa science is that it collapses a standardized intervention into a grocery-store food story. The COSMOS trial did not test candy bars. It tested a defined cocoa extract dose under controlled conditions. That matters because processing can substantially reduce flavanol content, and many commercial chocolate products add sugar, fats, and calories without delivering a reliable amount of bioactive flavanols. Reviews on cocoa processing and health effects consistently note that the health value of cocoa depends heavily on flavanol preservation, dose, and formulation. 

So when people ask whether this means they should just eat more chocolate, the responsible answer is: not necessarily. The evidence supports standardized cocoa flavanol exposure, not indiscriminate chocolate consumption. That is a very different thing.

What the broader research says

The new 2025 inflammaging paper did not appear in a vacuum. The larger COSMOS trial, published in The American Journal of Clinical Nutrition in 2022, found that cocoa extract supplementation did not significantly reduce the primary composite of total cardiovascular events, but it did reduce cardiovascular disease death by 27%. Per-protocol analyses also supported a possible reduction in total cardiovascular events among adherent participants. That is not the same as saying cocoa is a replacement for medical therapy, but it does strengthen the idea that the biomarker findings may have real-world relevance. 

Other systematic reviews and meta-analyses point in the same general direction. Cocoa flavanols have been associated with improved endothelial function, modest blood pressure lowering, and improved oxidative-stress or inflammatory profiles in adults, though the literature still shows heterogeneity in dose, population, and study duration. A 2024 meta-analysis concluded that dark chocolate and cocoa may improve systemic oxidative status and inflammation, while a 2020 meta-analysis found beneficial effects of dark chocolate and flavonoids on flow-mediated dilation. Earlier Cochrane and other meta-analyses also reported small but statistically significant blood pressure reductions from flavanol-rich cocoa products. 

There are also condition-specific findings. In peripheral artery disease, a randomized cocoa intervention improved walking-related outcomes and was linked to mitochondrial and antioxidant signaling changes, adding to the idea that cocoa’s value may extend beyond a single biomarker. 

What this means for ACEND users

From our perspective, the interesting question is not whether cocoa is trendy (chocolate will never go out of style). It is whether specific flavanol compounds help validate a broader systems-based inflammation strategy.

The answer appears to be yes.

The cocoa literature supports a model in which polyphenol-rich compounds can influence inflammatory tone, vascular biology, oxidative stress handling, and possibly downstream resilience in aging tissues. That aligns with the core ACEND view that chronic inflammation should be addressed through evidence-based clinical nutrition, not one-dimensional wellness language. Cocoa flavanols are not a standalone answer, but they are part of a growing body of evidence showing that food-derived bioactives can affect measurable biology when dose, standardization, and compliance are taken seriously. 

It also highlights an important discipline for consumers and practitioners: do not confuse a bioactive-rich extract with a loosely related food category. The clinically relevant question is always: what compound, at what dose, in what form, for how long, and measured against what outcome? The cocoa trial helps answer that more clearly than most nutrition headlines do. 

Practical takeaways

If you are thinking about cocoa flavanols purely from a healthy-aging standpoint, the most evidence-based summary right now is this:

Standardized cocoa flavanol supplementation may help lower hsCRP, support vascular function, and contribute to a healthier inflammatory profile over time. It should not be marketed as a proven anti-aging shortcut, and it should not be confused with eating more conventional chocolate products. The strongest current evidence centers on inflammation and cardiovascular physiology, with (–)-epicatechin standing out as one of the most plausible active contributors

Precision nutrition works best when we respect the details—bioactive identity, dose, formulation, and clinical context. That is exactly where the future of evidence-based inflammatory support is headed. This is why we formulate as we do.

References

1. Li S, et al. Effects of 2-year cocoa extract supplementation on inflammaging biomarkers in older US adults: findings from the COcoa Supplement and Multivitamin Outcomes Study randomised clinical trial. Age and Ageing.2025. DOI: 10.1093/ageing/afaf269. 
2. Sesso HD, et al. Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS). The American Journal of Clinical Nutrition.2022. 
3. Sun Y, Zimmermann D, De Castro CA, Actis-Goretta L. Dose-response relationship between cocoa flavanols and human endothelial function: a systematic review and meta-analysis of randomized trials. Food & Function. 2019. 
4. Behzadi M, et al. Effect of dark chocolate/cocoa consumption on oxidative stress and inflammation: a systematic review and meta-analysis. Clinical Nutrition. 2024. 
5. Ebaditabar M, et al. Effect of dark chocolate on flow-mediated dilatation: a systematic review and meta-analysis of randomized controlled trials. Clinical Nutrition ESPEN. 2020. 
6. Ried K, et al. Effect of cocoa on blood pressure. Cochrane Database of Systematic Reviews. 2012. 
7. Schroeter H, et al. (–)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. Proceedings of the National Academy of Sciences. 2006. 
8. Dicks L, et al. Effect of an (–)-Epicatechin intake on cardiometabolic biomarkers: a systematic review of randomized controlled trials. Nutrients. 2022. 

Other articles you may enjoy

• Microbiome, Mitochondria, and Chronic Inflammation: The Hidden Trifecta

SEO notes

Suggested SEO title: Cocoa Flavanols and Inflammation: What (–)-Epicatechin May Mean for Healthy Aging
Suggested slug: cocoa-flavanols-inflammation-epicatechin
Suggested secondary keyphrases: epicatechin and inflammation, cocoa flavanols healthy aging, cocoa extract hsCRP

Meta description (25 words):
New research suggests cocoa flavanols and epicatechin may help lower hsCRP, supporting vascular health and healthier inflammatory aging through evidence-based nutrition.

Note: Always consult with a healthcare professional before considering any treatment options or significant dietary changes.